Please assess the completion status of the following clinical trial:

Trial Title: Study of Efficacy and Safety of Omalizumab in Refractory Chronic Spontaneous Urticaria Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~* Diagnosis of chronic spontaneous urticaria refractory to H1 antihistamine at the time of randomization~* Chronic spontaneous urticaria diagnosis for 6 months~Key Exclusion Criteria:~* Weight less than 20 kg~* Clearly defined underlying etiology for chronic urticaria other than chronic spontaneous urticaria~* Evidence of parasitic infection~* Any other skin diseases than chronic spontaneous urticaria with chronic itching~* Previous treatment with omalizumab~* Contraindications to diphenhydramine~* History of anaphylactic shock~* History or current diagnosis of ECG abnormalities indicating significant risk of safety for patients participating in the study~* History of hypersensitivity to omalizumab or to drugs of similar chemical classes~* Pregnant or nursing (lactating) women

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Omalizumab 300 mg (Type: EXPERIMENTAL): Participants received omalizumab 300 mg subcutaneously every 4 weeks during the 12 week treatment period.
- Omalizumab 150 mg (Type: EXPERIMENTAL): Participants received omalizumab 150 mg subcutaneously every 4 weeks during the 12 week treatment period.
- Placebo (Type: PLACEBO_COMPARATOR): Participants will receive placebo subcutaneously every 4 weeks during the 12 week treatment period.

Based on this trial design, predict the completion outcome and termination type (if applicable).